JP2023518269A5 - - Google Patents

Info

Publication number
JP2023518269A5
JP2023518269A5 JP2022556252A JP2022556252A JP2023518269A5 JP 2023518269 A5 JP2023518269 A5 JP 2023518269A5 JP 2022556252 A JP2022556252 A JP 2022556252A JP 2022556252 A JP2022556252 A JP 2022556252A JP 2023518269 A5 JP2023518269 A5 JP 2023518269A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
mesylate
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518269A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/022997 external-priority patent/WO2021188815A1/en
Publication of JP2023518269A publication Critical patent/JP2023518269A/ja
Publication of JP2023518269A5 publication Critical patent/JP2023518269A5/ja
Pending legal-status Critical Current

Links

JP2022556252A 2020-03-18 2021-03-18 Ｃｏｖｉｄ－１９のための吸入療法 Pending JP2023518269A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062991561P 2020-03-18 2020-03-18
US62/991,561 2020-03-18
PCT/US2021/022997 WO2021188815A1 (en) 2020-03-18 2021-03-18 Inhalational therapy for covid-19

Publications (2)

Publication Number Publication Date
JP2023518269A JP2023518269A (ja) 2023-04-28
JP2023518269A5 true JP2023518269A5 (enExample) 2024-03-27

Family

ID=77771385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556252A Pending JP2023518269A (ja) 2020-03-18 2021-03-18 Ｃｏｖｉｄ－１９のための吸入療法

Country Status (5)

Country Link
US (1) US20230165826A1 (enExample)
EP (1) EP4121037A4 (enExample)
JP (1) JP2023518269A (enExample)
CA (1) CA3171958A1 (enExample)
WO (1) WO2021188815A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021202708A1 (en) * 2020-03-31 2021-10-07 Ensysce Biosciences, Inc. Methods for treating viral infections with nafamostat
EP4267125A4 (en) * 2020-12-22 2024-06-26 Ege Universitesi Development of an innovative inhalation formulation of nafamostat mesylate for the management of covid-19
CN118121605B (zh) * 2024-02-28 2025-09-09 中国科学院武汉病毒研究所 去甲乌药碱在防治新型冠状病毒中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0859503A (ja) * 1994-08-26 1996-03-05 Teijin Ltd ペプチド・蛋白質性薬物の経口、経粘膜投与用リポソーム製剤
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP2003089632A (ja) * 2001-09-17 2003-03-28 Otsuka Pharmaceut Factory Inc 注射用水性製剤
JP2005139085A (ja) * 2003-11-04 2005-06-02 Ono Pharmaceut Co Ltd 顆粒
AU2004311478A1 (en) * 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
DE102011108346A1 (de) * 2011-07-25 2013-01-31 Philipps-Universität Marburg Verwendung von Hemmstoffen der TMPRSS2 als Arzneimittel
BR112015003851A2 (pt) * 2012-08-21 2017-08-08 Glaxo Group Ltd composições compreendendo um domínio variável único e mesilato de camostato (cm)
RU2622747C2 (ru) * 2015-10-22 2017-06-19 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) Способ и средство для лечения реактивного артрита хламидийной этиологии
JP2023512628A (ja) * 2020-01-21 2023-03-28 アカデミー オブ ミリタリー メディカル サイエンシズ ＳＡＲＳ－ＣｏＶ－２感染症の治療における安息香酸塩化合物の利用

Similar Documents

Publication Publication Date Title
Kumar et al. Intranasal drug delivery: A non-invasive approach for the better delivery of neurotherapeutics
JP2023518269A5 (enExample)
ES2218543T3 (es) Procedimiento y preparacion para la administracion de insulina por via pulmonar.
Marttin et al. Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits
JP2774379B2 (ja) 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途
JP2009256353A (ja) 肺臓内領域における活性成分のキャリヤーとしての半フッ素化アルカンの吸入及び点滴注入による使用
TW200301131A (en) Pulmonary delivery of aminoglycosides
WO2008025560A1 (en) Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
BRPI0707641A2 (pt) antibiàticos nebulizados para terapia de inalaÇço
JP2009510077A (ja) 抗生物質製剤、単位用量、キットおよび方法
JP6397984B2 (ja) 乾燥粉末ペプチド医薬
ES2339423T3 (es) Composiciones terapeuticas para administracion pulmonar.
JP6072801B2 (ja) アルベカシンを含有する水性組成物
Liu et al. Pulmonary delivery of scutellarin solution and mucoadhesive particles in rats
BR112018074551B1 (pt) Aerossol farmacêutico, composições farmacêuticas líquida e sólida, kit, e, método para preparar e dispensar um aerossol
CN114652704A (zh) 一种曲前列尼尔软雾吸入剂
JPH05509101A (ja) 経粘膜薬物製剤および経粘膜投与法
JP2013539784A (ja) 嚢胞性線維症の吸入デヌホソルでの治療方法
CN102743339B (zh) 一种碱性磷酸酶纳微颗粒及其制备方法
CN116472033A (zh) 用于经鼻施用的钴胺素化合物的药物组合物
KR20140073745A (ko) 폐질환 치료용 흡입 제형 및 이의 제조방법
CN114632075B (zh) 一种伏立康唑雾化吸入剂和用途
EP4304552A1 (en) Novel antiviral compositions and their use in therapy and in the treatment of viral infections
CN111544420A (zh) 可吸入泡腾粉雾剂及其在制备感染性肺炎药物中的应用
CN121243075A (zh) 一种用于肺纤维化急性加重期的靶向脂质体纳米药物制剂及其制备方法和应用